Montreal classification of inflammatory bowel disease
Gastroenterology and hepatology
Also known as: Montreal-Klassifikation (Morbus Crohn, Colitis ulcerosa) · Montreal sınıflaması (inflamatuvar barsak hastalığı)
What it is for
Phenotype classification of Crohn's disease (age, location, behaviour) and of ulcerative colitis (extent, severity); it was derived from the earlier Vienna classification of Crohn's disease.
Classification
| Category | Description |
|---|---|
| Crohn's disease – age at diagnosis | A1 16 years or younger; A2 17–40 years; A3 over 40 years |
| Crohn's disease – location | L1 ileal; L2 colonic; L3 ileocolonic; L4 isolated upper gastrointestinal disease, added to L1–L3 when both are present (e.g. L3+L4) |
| Crohn's disease – behaviour | B1 non-stricturing, non-penetrating; B2 stricturing; B3 penetrating; the modifier p is added for perianal disease (e.g. B2p) |
| Ulcerative colitis – extent | E1 ulcerative proctitis (rectum only); E2 left-sided colitis (distal to the splenic flexure); E3 extensive colitis (proximal to the splenic flexure) |
| Ulcerative colitis – severity | S0 clinical remission; S1 mild (4 or fewer stools a day with or without blood, no systemic illness); S2 moderate (more than 4 stools a day, minimal signs of systemic toxicity); S3 severe (at least 6 bloody stools a day with signs of systemic toxicity: pulse 90/min or more, temperature 37.5 °C or more, haemoglobin below 10.5 g/dL, erythrocyte sedimentation rate (ESR) 30 mm/h or more) |
Source
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
Can J Gastroenterol 2005;19 Suppl A:5A–36A (Silverberg MS et al.)
DOI: 10.1155/2005/269076
PMID: 16151544
- Edition
- Montreal classification (Working Party, Montreal World Congress 2005), in current use
- Checked on
Summary of the published classification in our own words. Not a substitute for the original publication.
A question about this classification?
Medelix answers clinical questions from guidelines and studies – every statement with its source.